Drug intelligence / Profile preview

sipoglitazar

Development stage: Discontinued
Lead developer: Takeda
Modality: Small Molecules
Administration: Oral

Overview

Sipoglitazar (TAK-654) is a novel, orally active pan-peroxisome proliferator-activated receptor (PPAR) agonist that targets the alpha (α), delta (δ), and gamma (γ) isoforms. Developed by Takeda Pharmaceuticals, it was primarily investigated for the treatment of type 2 diabetes mellitus and associated metabolic disorders. By activating the PPAR family of nuclear receptors, sipoglitazar regulates the expression of genes involved in glucose and lipid metabolism, aiming to improve insulin sensitivity and lipid profiles. Although it reached clinical development, Takeda eventually discontinued the program.

Targets

PPARA (Peroxisome proliferator-activated receptor alpha)PPARG (Peroxisome proliferator-activated receptor gamma)PPARD (Peroxisome proliferator–activated receptor delta)

Beyond the preview

Go deeper on sipoglitazar.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sipoglitazar.